The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs

Ravulizumab is a very expensive complement C5‐inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed‐dosing interval of 8 weeks. For lifelong treatment, a cost‐effective and patient‐friendly dosing strategy is preferred. We therefore explored alternative ravulizumab dosing...

Descripción completa

Detalles Bibliográficos
Autores principales: ter Avest, Mendy, Langemeijer, Saskia M.C., Schols, Saskia E.M., Burger, David M., van de Kar, Nicole C.A.J., Blijlevens, Nicole M.A., Kievit, Wietske, ter Heine, Rob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359320/
https://www.ncbi.nlm.nih.gov/pubmed/33512711
http://dx.doi.org/10.1111/bcp.14748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359320/
https://www.ncbi.nlm.nih.gov/pubmed/33512711
http://dx.doi.org/10.1111/bcp.14748

Ejemplares similares